admin

Robert Gourdie, a trailblazing cardiovascular scientist at the Fralin Biomedical Research Institute at VTC, is the first Virginia Tech researcher to receive an Outstanding Investigator Award from the National Institutes of Health (NIH).

The seven-year, $6.4 million grant is funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the NIH. Known as an R35, the grant provides Gourdie with increased freedom to carry out inventive research concepts that aren’t tethered to specific, finite projects.

Image: Robert Gourdie, the Commonwealth Research Commercialization Fund Eminent Scholar in Heart Reparative Medicine Research and director of the Fralin Biomedical Research Institute’s Center for Vascular and Heart Research, is Virginia Tech’s first recipient of a National Institutes of Health Outstanding Investigator Award. Photo by Clayton Metz for Virginia Tech.

March 2, 2022 — The U.S. Centers for Medicare and Medicaid Services (CMS) will offer reimbursement for software from Medimaps Group that performs osteoporosis risk fracture assessment via trabecular bone scores (TBS).

The agency assigned the Current Procedural Terminology (CPT) code 77089 for Medimaps’ TBS iNsight, which provides a trabecular bone score for x-ray and dual-energy x-ray absorptiometry. It was effective January 2022.

Image: https://www.auntminnie.com

Foresite Capital, a firm that invests in early-stage healthcare and life sciences companies, today launched a $173 million fund designed to further finance startups launched by its Foresite Labs entrepreneurial innovation hub.

The new fund will be one source of capital for Foresite Labs startups, which will continue to be funded through the $969 million raised last year by Foresite Capital—consisting of the $775-million Fund V and a $193.75 million fund for selectively making additional investments in their highest conviction Fund V portfolio companies, called the Opportunity Fund.

Image: Vikram (Vik) Bajaj, PhD, a managing partner with Foresite Capital and the Co-Founder and CEO of the firm’s Foresite Labs entrepreneurial innovation hub.

SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is teaming up with the National Kidney Foundation (NKF) to support National Kidney Month initiatives aimed at improving outcomes for kidney transplant recipients and those suffering from kidney failure.

This marks the seventh consecutive year that CareDx is supporting NKF’s Kidney Patient Summit on Capitol Hill, which is taking place virtually this year on March 2, 2022. Patient representatives will be advocating for more research funding to accelerate the early detection of chronic kidney disease, which could help physicians reverse or delay the need for transplantation.

Maryland is home to one of the largest life science clusters in the nation. According to the Maryland Department of Commerce, the State has nearly 2,300 life science companies and 476 private research and development biotechnology firms (NAICS 541714), which represents 5.3% of this U.S. industry.

Some of the nation’s most important research occurs within Maryland at National Institute of Health (NIH), Food & Drug Administration (FDA), federal laboratories, Johns Hopkins, and the University of Maryland. In fiscal year 2018, Maryland received $1.5 billion from NIH for biomedical research, behind four other states (NIH 2018 report):

Image: https://www.americangene.com

D&D Pharmatech, a clinical-stage global biotech company, features a strong research emphasis, with focus on neurodegenerative brain disorders led by Johns Hopkins University School of Medicine neuroscientists, including Ted M. Dawson, MD, PhD, who is a globally recognized authority in this domain.

The company’s founder Lee Seulki, PhD, 45, also working at the university as a radiology professor, is a promising medical scientist who is the youngest `Highly Cited Researcher` named by Clarivate Analytics in 2017.

Ron Kurz, Sr. Director & GM at Canon Virginia, Inc., joins BioTalk to discuss his career, growth opportunities, and Canon’s role in the BioHealth Capital Region

Listen now via Apple https://apple.co/35BlOgJ, Google https://bit.ly/36DvurG, Spotify https://spoti.fi/3sqk8jo, Amazon https://amzn.to/3598voh, and TuneIn https://bit.ly/3Itb16Y